Jul. 22 at 9:04 PM
$ASRT I'm assuming they filed for an extension. Looking at another company that was in similar situation (SHOT), it takes about a week for Nasdaq to reply. There shouldn't be any issue on them not getting an extension (baring something we don't know). Then it's a matter of waiting till Q2 report to see if the comments from Q4 and Q1 cc call start to play out, at some initial level, with Rolvedon and Sympazan revenue growth occurring. I think the easiest money is between here and
$1.20----all they need to do is show progress and no reverse split. To really make this investment worthwhile they need to lower costs, grow revenue, clean up more of the lawsuits, and figure out how they are going to acquire a great product line for sub
$100M (or tempt someone to acquire them instead).
